Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Psychoneuroendocrinology. 2018 Apr 6;93:29–38. doi: 10.1016/j.psyneuen.2018.04.003

Figure 4.

Figure 4

Effect of intra-amygdala nano-injections of V1R antagonist on SL-induced active coping behavior. (A) Time (s) spent mobile during SS after bilateral nano-injections of a VP V1R antagonist into the amygdala. (B) Cage crossings in an observation chamber over 15 min as a measure of generalized locomotor activity. (C) Histological verification of nano-injection sites in the CeA and BLA. Image shows cannula track (track damage), optic nerve (opt) injection site (inj. site), and amygdala sub regions; Data are mean ± SEM. **P < 0.01 significant difference from within drug treatment group compared to tap water controls with Bonferroni’s post hoc multiple comparisons test. # # P < 0.01 indicated significant main effect of V1R antagonist with a two-factor ANOVA. Sample size per data point are n = 5 – 8.